GenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
20.04.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system . Seite 1
A new medical facility at UPMC Mercy Pavilion in Pittsburgh’s Uptown section will marry for the first time the disciplines of ophthalmology and rehabilitation — and top doctors in those fields — when it opens this week. “To my knowledge, this is the first physical space that will be bringing
Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024 38 patients
/PRNewswire/ The Foundation Fighting Blindness, the world s leading organization committed to finding treatments and cures for blinding retinal diseases, is.